ERBB2 and breast cancer: If the addition of pertuzumab to NST with trastuzumab increases the axillary pCR rate and subsequently increases the total breast and axillary pCR rates, dual HER2 blockade may further reduce the frequency of axillary surgery for patients with clinically node‐positive, HER2‐positive breast cancer.